X

Trial Profile

Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Factor VIII/von Willebrand factor (Primary)
Indications Von Willebrand disease
Focus Adverse reactions; Therapeutic Use
Acronyms OPALE
Sponsors CSL Behring

Most Recent Events

26 Feb 2024 Status changed from active, no longer recruiting to completed.
01 Jul 2022 Results assessing the effectiveness and safety of Voncento R, a plasma-derived FVIII/VWF concentrate (ratio 1:2.4), administrated in LTP published in the European Journal of Haematology
10 Jan 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com